Claire Mathiot
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments 41
- Oncology top 0.5%
- Cancer Cells and Metastasis 17
- Peptidase Inhibition and Analysis 12
- Cancer Treatment and Pharmacology 12
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 11
- Genetics top 2%
- Molecular Biology top 5%
- Protein Degradation and Inhibitors 15
- Glycosylation and Glycoproteins Research 11
-
- Monoclonal and Polyclonal Antibodies Research 18
- Co-authors
- François‐Clément BidardJean‐Yves PiergaThierry FaçonPhilippe MoreauMichel AttalHervé Avet‐LoiseauGérald MaritWolf H. Fridman
- Cited by
- HematologyOncologyCancer Research
- Partner nations
- FranceBelgiumUnited States
In The Last Decade
Claire Mathiot
112 papers receiving 4.7k citations
Peers
Comparison fields: 5 of 111
- Hematology 2.1k
- Oncology 2.7k
- Cancer Research 1.0k
- Genetics 408
- Molecular Biology 2.3k
Countries citing papers authored by Claire Mathiot
This map shows the geographic impact of Claire Mathiot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Mathiot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Mathiot more than expected).
Fields of papers citing papers by Claire Mathiot
This network shows the impact of papers produced by Claire Mathiot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Mathiot. The network helps show where Claire Mathiot may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Claire Mathiot, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 152 | |
| 2 | 2010 | 92 | |
| 3 | 2010 | 298 | |
| 4 | 2010 | 119 | |
| 5 | Bortezomib Plus Dexamethasone Versus Reduced-dose Bortezomib Plus Thalidomide-dexamethasone As Induction Prior To Autologous Transplantation in Newly Diagnosed Myeloma | 2010 | 4 |
| 6 | 2009 | 266 | |
| 7 | 2007 | 1 | |
| 8 | 2004 | 6 | |
| 9 | 2002 | 25 | |
| 10 | 2002 | 88 | |
| 11 | 1999 | 39 | |
| 12 | 1995 | 92 | |
| 13 | 1994 | 18 | |
| 14 | 1994 | 98 | |
| 15 | 1993 | 33 | |
| 16 | 1991 | 9 | |
| 17 | 1990 | 11 | |
| 18 | 1989 | 18 | |
| 19 | 1989 | 15 | |
| 20 | [Multifocal chloroma (granulocytic sarcoma), without marrow involvement. One case (author's transl)]. | 1978 | 2 |
About Claire Mathiot
Claire Mathiot is a scholar working on Hematology, Oncology, Immunology, Cancer Research and Genetics, having authored 116 papers that have together received 4.9k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (41 papers), Monoclonal and Polyclonal Antibodies Research (18 papers), Cancer Cells and Metastasis (17 papers), Protein Degradation and Inhibitors (15 papers), Peptidase Inhibition and Analysis (12 papers), Cancer Treatment and Pharmacology (12 papers), Glycosylation and Glycoproteins Research (11 papers) and Cancer Genomics and Diagnostics (11 papers). The work is most often cited by research in Hematology (2.1k citations), Oncology (2.7k citations), Cancer Research (1.0k citations), Genetics (408 citations) and Molecular Biology (2.3k citations). Claire Mathiot has collaborated with scholars based in France, Belgium and United States. Frequent co-authors include François‐Clément Bidard, Jean‐Yves Pierga, Thierry Façon, Philippe Moreau, Michel Attal, Hervé Avet‐Loiseau, Gérald Marit, Wolf H. Fridman, Suzette Delaloge and Étienne Brain. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, Annals of Oncology and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.